Scientist pointing at a computer screen displaying a petri dish with bacterial colonies and a color-coded chart, used for laboratory analysis.

Acute gastroenteritis

Clinical studies show strong evidence that children and adults with acute gastroenteritis benefit from the administration of BioGaia ProTectis.

<

Acute gastroenteritis

This may cause diarrhoea and other stomach problems, a condition called antibiotic associated diarrhoea (AAD). Other symptoms such as bloating, stomach pain and other functional abdominal symptoms may also occur.

Acute gastroenteritis (AGE) is an inflammation of the gastrointestinal tract. It affects both the gastric mucosa as well as the small intestine and can cause loose or liquid stools several times during a day. The child may have a fever and vomit and the symptoms may persist for 1-2 weeks.

In countries with good child care, the disease is mild and rarely lead to death, but might still require hospitalization, which is often associated with a lot of suffering and high costs.

Several systematic reviews have found probiotics to be effective in reducing the duration of diarrhoea in children and adults.

Amongst those Shornikova showed that after 2days of treatment with BioGaia 74 % of the patients have been free from watery diarrhoea and vomiting – published 1997 in the medical journal J. Pediatr. Gastroenterol. Nutr.

Also the study from Francavilla published in 2012 showed the efficacy and safety of BioGaia Protectis while treating children with acute watery diarrhoea.

BioGaia Probiotic Drops and Tablets

Containing Limosilactobacillus reuteri Protectis, BioGaia Pobiotic Drops and Tablets promote the growth of good bacteria in the intestinal tract, re-establishing a healthy bacterial balance and thus significantly reduce the duration of watery diarrhoea and even increase the resistance.

BioGaia Dosage recommendations for acute diarrhoea:

1-2 times 5 drops or 1 tablet daily

Prospective, randomized, placebo controlled study

Limosilactobacillus reuteri as a therapeutic agent in acute diarrhoea in young children.

Shornikova AV et al. J. Pediatr. Gastroenterol. Nutr. 1997;24:399-404.
Significant faster recovery from watery diarrhoea in hospitalised children supplemented with Limosilactobacillus reuteri Protectis.

Result

74%

free from watery diarrhoea day 2 with L. reuteri (BioGaia) compared to 19% in the placebo group.

Conclusions

  • The benefits of L. reuteri (BioGaia) were observed within 24 hours of onset of treatment.
  • A significant effect was apparent from the second day of treatment when 74% of patients receiving BioGaia were free from watery diarrhoea compared to 19% in the control group.
  • Vomiting practically stopped after the first day of treatment after the intake of L. reuteri (Bio- Gaia) , while it continued in the placebo group.

Facts

  • Prospective, randomized, placebo controlled study
  • 40 children aged 6-36 months hospitalised due to acute diarrhoea , 75% affected by Rotavirus
  • 1010-1011 CFU Limosilactobacillus reuteri (BioGaia) (n=19) or placebo (n=21) for 5 days
  • Both received standard rehydration therapy.

Double blind study

Limosilactobacillus reuteri DSM 17938 vs placebo in children with acute diarrhoea.

Francavilla R et al. (2012) Randomised clinical trial: Aliment Pharmacol Ther. 36: 363-369.

Bar chart comparing multiple data points with yellow and gray bars of varying heights, labeled with specific values and grouped into different categories.

Conclusions

  • reuteri Protectis (BioGaia) significantly reduced the duration of watery diarrhoea as compared with placebo
  • Children receiving L. reuteri Protectis (BioGaia) had significantly lower relapse rate of diarrhoea.

Facts

  • Double blind, placebo-controlled study
  • 74 children aged 6-36 months hospitalised due to acute diarrhoea, 75% affected by Rotavirus
  • 4x108CFU Limosilactobacillus reuteri Protectis (BioGaia) (n=19) or placebo (n=21) for 5 days
  • Both received standard rehydration therapy